Novo Nordisk's Once-Weekly Insulin Awiqli Wins FDA Approval; $15B+ in Pharma Deals

Three years. That's how long Novo Nordisk waited for today — FDA approval for Awiqli, the first once-weekly basal insulin, landing alongside fifteen billion dollars in deals in a single Friday session.

Plus AstraZeneca's COPD antibody delivers a Phase 3 double win in a broader population than anyone expected, and Rocket Pharmaceuticals finally gets its gene therapy across the finish line after years of setbacks. Big Friday — let's unpack it.

Welcome to The Pharma Closeout for Friday, March 27, 2026. I'm Alex Mercer.

And I'm Maya Patel. Let's go.

Top story — Novo Nordisk has FDA approval for Awiqli, insulin icodec, a once-weekly basal insulin for adults with type 2 diabetes. We're talking a 700 units-per-mL injection that collapses basal insulin dosing from seven shots a week down to one. Novo says they expect a U.S. launch in the second half of this year.

Three years from submission to approval. That is not a routine timeline. That kind of delay almost always means extended cardiovascular safety discussions with the agency, labeling scope negotiations, or both. What matters now is the final label language — whether it constrains the treatable population in ways that limit commercial uptake.

And the commercial stakes here are staggering. The global insulin market exceeds twenty billion dollars a year. Sanofi's Lantus and Toujeo franchise, Lilly's daily insulins — every one of those products wakes up in a fundamentally different competitive world today. Once-weekly dosing is the kind of convenience story that practically sells itself at the formulary negotiation table.

Hold on though — convenience sells in a press release. At the prescriber level, the calculus is different. Weekly dosing means slower titration cycles. For patients with significant glycemic variability, you're adjusting dose every week instead of every day, which means it takes longer to find the right dose and longer to correct if you overshoot. That real-world titration experience is going to determine whether endocrinologists reach for this first-line or reserve it for stable patients already well-controlled on daily regimens.

Fair point. And Novo is launching this into a stretched commercial environment. They're simultaneously defending Ozempic, scaling higher-dose Wegovy, managing payer relationships across all of those assets. That's a lot of competing priorities for one field force and one market access team.

The launch math gets complicated fast. Novo has to price Awiqli high enough to justify the innovation premium but low enough to win formulary placement against daily insulins that are approaching generic territory. If they thread that needle, this is a multi-billion-dollar franchise within three to four years. If they don't, Awiqli becomes a premium convenience niche — clinically differentiated but commercially constrained. The second-half launch trajectory will separate those two scenarios quickly.

Shifting to the deal side, and this is one of the busiest Fridays we've seen in months. Three major transactions, starting with Novartis. They announced a deal worth up to two billion dollars to acquire Excellergy, a private biotech developing Exl-111 — a next-generation anti-IgE antibody currently in Phase 1. What makes Exl-111 distinct, according to the Novartis press release, is that it's a half-life extended, high-affinity antibody designed to strip IgE molecules that are already bound to immune cell receptors. That's a different mechanism from what's currently available. With Xolair biosimilars now bearing down on them, Novartis is building the succession plan before the franchise erodes. Transaction expected to close second half of this year.

Second deal, and this one warrants the deep dive — let's bring in Marcus Webb on the Otsuka-Transcend transaction.

And the third — CVC Capital Partners tabling a twelve-point-six-billion-dollar offer to fully acquire Recordati, the Italian specialty pharma. CVC already holds a major stake, so this is a consolidation move. Private equity looking at Recordati's cash-flow profile and deciding the math works better with full ownership and operational control.

Fifteen billion in aggregate across three deals in one session. But what's striking isn't just the volume — it's the strategic divergence. Novartis is playing lifecycle defense. Otsuka is making a high-conviction bet on a therapeutic area most acquirers won't touch. CVC is running a PE cash-flow arbitrage. Three completely different theses about where value sits right now, all landing on the same Friday. If anyone was wondering whether deal appetite was cooling into Q2, this is your answer.

On the regulatory front — beyond Awiqli, the other approval that matters today is Rocket Pharmaceuticals. The FDA granted accelerated approval to KRESLADI — RP-L201 — an autologous lentiviral hematopoietic stem cell gene therapy for pediatric patients with severe LAD-I who lack an HLA-matched sibling donor. This is Rocket's first commercial product, and the FDA also granted a Rare Pediatric Disease Priority Review Voucher alongside it.

Rocket has been fighting for this one. A prior Complete Response Letter, manufacturing concerns, what Endpoints described as years of setbacks. The approval validates the platform, but the commercial runway is inherently narrow. They're reportedly planning a limited launch, which makes sense — in an ultra-rare population, you're identifying patients one at a time.

The accelerated approval was based on sustained increases in neutrophil CD18 and CD11a surface expression — so we're talking a surrogate endpoint, not clinical outcomes. Confirmatory data will determine whether this label holds. For Rocket's near-term financials, the Priority Review Voucher could actually generate more immediate value than product revenue — recent vouchers have traded in the hundred-million-dollar range, and the severe LAD-I patient population is measured in dozens per year, not thousands. The long-term investment thesis rests on whether this platform extends to their other gene therapy programs in the pipeline.

Also worth noting on the regulatory front — the European CHMP recommended approval of a subcutaneous formulation of Sanofi's Sarclisa, isatuximab, plus four additional new medicines. The subQ reformulation compresses infusion time from hours to minutes in the myeloma setting.

The competitive context here is J&J's Darzalex Faspro, which already has the subQ advantage and dominant market share. Sanofi closing that convenience gap is necessary but not sufficient. Whether this recommendation actually translates into share recapture or just slows the bleed — that depends on European Commission timing and Sanofi's willingness to compete on access, not just delivery format.

Now the data story everyone will be talking about heading into the weekend. AstraZeneca reported that tozorakimab, their anti-IL-33 antibody, hit primary endpoints in both the OBERON and TITANIA Phase 3 trials in COPD — statistically significant and clinically meaningful reductions in moderate-to-severe exacerbations versus placebo. AstraZeneca shares climbed roughly three percent in premarket on the news. Full data presentations are coming at an upcoming medical conference.

Two things stood out to me. First, the efficacy held across former smokers and the broader enrolled population — that wider-than-anticipated responder profile could meaningfully expand the commercial opportunity beyond initial market models. Second, and this is the piece that matters for the field — AstraZeneca's press release described tozorakimab as the first IL-33-targeting biologic to demonstrate these exacerbation reductions in replicate Phase 3 COPD trials. If the full dataset confirms that at conference, this isn't just an AstraZeneca pipeline win. It validates IL-33 as a druggable pathway in COPD, which reshapes the competitive map for GSK's depemokimab and every other respiratory biologic in development.

One more from AstraZeneca before we close — they also disclosed early in vivo CAR-T data in multiple myeloma showing efficacy signals, but with one patient death in a China-based trial. In vivo CAR-T eliminates the ex vivo manufacturing bottleneck, which is potentially transformative. But a fatal safety event this early will draw intense regulatory scrutiny. The risk-benefit conversation for this platform just got more complex, and it's worth watching closely as the clinical program advances.

That is your Pharma Closeout for Friday, March 27th. Awiqli landing after three years and reshaping the insulin landscape. KRESLADI giving Rocket its first commercial gene therapy. Novartis, Otsuka, and CVC deploying fifteen billion dollars across three very different bets. And tozorakimab potentially opening a new biologic class in COPD. This industry does not take Fridays off — and honestly, we love it. If this briefing saves you time, follow us on Spotify and drop a rating. It helps more people in this space find us. We're back Sunday with the full week in review.

Go enjoy the weekend, everyone. We'll see you Sunday. ### Episode Metadata **Title:** Novo Nordisk's Once-Weekly Insulin Awiqli Wins FDA Approval; $15B+ in Pharma Deals; AstraZeneca COPD Phase 3 Wins | Mar 27, 2026 **Description:** FDA approves Novo Nordisk's Awiqli, the first once-weekly basal insulin, after a three-year regulatory journey. Plus Novartis bets $2B on a next-gen Xolair successor, Otsuka acquires Transcend for $700M upfront, and AstraZeneca's tozorakimab delivers dual Phase 3 wins in COPD. Rocket Pharmaceuticals lands its first gene therapy approval for severe LAD-I. **Tags:** Awiqli, insulin icodec, Novo Nordisk, FDA approval, once-weekly insulin, diabetes, Novartis, Excellergy, Xolair, Otsuka, Transcend Therapeutics, PTSD, neuropsychiatry, CVC Capital, Recordati, AstraZeneca, tozorakimab, COPD, Rocket Pharmaceuticals, KRESLADI, gene therapy, LAD-I, Sarclisa, Sanofi, CHMP, pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, M&A, deals #